Latest Pluripotency Stories

Developed with Harvard University, TaqMan® hPSC Scorecard(TM) Panel provides a benchmark against which researchers can evaluate pluripotency and potential of cell lines CARLSBAD, Calif., June 12, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today launched the TaqMan® hPSC Scorecard(TM) Panel, a first-of-its-kind characterization assay that establishes a standardized benchmark against which researchers can now evaluate pluripotency and trilineage differentiation...

MADISON, Wis., Aug. 14, 2012 /PRNewswire/ -- CeeTox and Cellular Dynamics International (CDI) today announced the introduction of a new, highly predictive cardiac safety screening service that utilizes human induced pluripotent stem (iPS) cell-derived cardiomyocytes. The Cardiac Arrhythmia Assessment Screen(TM) (CAAS) combines CeeTox's expertise with in vitro toxicity screening and CDI's iCell® Cardiomyocytes to provide a comprehensive profile of drug-induced cardiac toxicity...

Even after being frozen for 18 years, human embryos can be thawed, grown in the laboratory, and successfully induced to produce human embryonic stem (ES) cells, which represent a valuable resource for drug screening and medical research. Prolonged embryonic cryopreservation as an alternative source of ES cells is the focus of an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. The article is available free online at the...

Connie K. Ho for redOrbit.com – Your Universe Online Stem cell research is gaining headway, but is still controversial. Scientists hope that a new discovery regarding stem cells from amniotic fluid will pave the way to an alternative option. A collaborative group of researchers recently discovered that stem cells in amniotic fluid can be changed into a more flexible state, which could possibly open another option to embryonic stem cells. The study was recently published in the journal...

Regenerative Medicine Institute research sheds new light on cell death in a common, lethal genetic disease in children, suggesting paths for potential treatment Cedars-Sinai's Regenerative Medicine Institute has pioneered research on how motor-neuron cell-death occurs in patients with spinal muscular atrophy, offering an important clue in identifying potential medicines to treat this leading genetic cause of death in infants and toddlers. The study, published in the June 19 online...

STEMCELL Technologies Inc. to Launch TeSR-E8 - a Novel Medium for Human Embryonic and Induced Pluripotent Stem Cells - and New STEMdiff Kits for Differentiation of these cell types Vancouver, British Columbia (PRWEB) June 12, 2012 STEMCELL Technologies Inc. (STEMCELL) announced today its plans to release a series of new products to advance research and translational applications for human pluripotent stem cells. These novel products, which will be launched at the International Society for...

CARLSBAD, Calif., June 12, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced a partnership with Cellular Dynamics International (CDI), the world's largest producer of human cells derived from induced pluripotent stem (iPS) cells, to commercialize a set of three new products optimized to consistently develop and grow human iPS cells for both research and bioproduction. The partnership marries CDI's leadership in human iPS cell development with Life...

SAN DIEGO, June 11, 2012 /PRNewswire/ -- Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. BD(TM) SMC4 is a patent protected, pre-formulated cocktail of small molecules for improving cellular reprogramming efficiencies and for enabling single-cell passaging and flow...

MADISON, Wis., June 7, 2012 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell(TM) Services. These services include novel iPS cell line reprogramming, genetic engineering and differentiation of iPS cells into commercially available iCell® terminal tissue cells (for example, heart or nerve cells). "CDI's mission is to be...

A New York Stem Cell Foundation (NYSCF) scientist has shown in new research that human embryonic stem cells can be used to grow bone tissue grafts for use in research and potential medical applications. Dr. Darja Marolt, an investigator at the NYSCF, is the lead author of the study, which was published this week in the online edition of the Proceedings of the National Academy of Sciences (PNAS). It is the first example of using bone cell progenitors derived from human embryonic stem...